Liver cancer is a prevalent malignant tumor globally. The newly approved first-line drug,
donafenib, is a novel oral small molecule multi-tyrosine kinase inhibitor that has significant …

To discover potential cytotoxic agents, new semi-synthetic phenoxy acetamide derivatives,
compound I and compound II, were synthesized, characterized, and screened for their …

Poly (ADP-ribose) polymerase 1 (PARP-1) is a critical enzyme involved in DNA damage
repair and recombination, and shows great potential for drug development in the treatment …

Cancer is imposing a global health burden because of the steady increase in new cases.
Moreover, current anticancer therapeutics are associated with many drawbacks, mainly the …

Background. The DNA repair enzyme poly (ADP‐ribose) polymerase (PARP) is involved in
DNA damage repair and cell death. However, the association between PARP's biological …

Abstract Poly (ADP-ribose) polymerase1 (PARP1) has been reported as a possible target for
chemotherapy in many cancer types. However, its action mechanisms and clinical …

Synthetic lethality describes situations in which defects in two different genes or pathways
together result in cell death. This concept has been applied to drug development for cancer …

Olaparib, a potent PARP inhibitor, has been shown to have great anti-tumor effects in some
tumor types. Although biliary tract cancer (BTC) is a good candidate for DNA damage …

Abstract Although Olaparib (Ola, a PARP-inhibitor), in combination with other
chemotherapeutic agents, was clinically approved to treat prostate cancer, but cytotoxicity …

Hepatocellular carcinoma is the most frequent primary liver cancer leading to a major health
problem worldwide, with a lack of effective therapies after diagnosis. Paradol, a phenolic …